SCHEMBL444560

SCHEMBL444560

O=C(O)C1CCN(C2CC(c3ccccc3)C2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.56
AKR1C1 Q04828 1/20 0.56
SLC18A3 Q16572 2/20 0.50
GRIN2B Q13224 3/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
LTA4H P09960 1/20 0.48
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
AGTR2 P50052 3/20 0.47
DPP4 P27487 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HRH1 P35367 1/20 0.45
HTR2B P41595 1/20 0.45
NOTUM Q6P988 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1587410 0.92 AKR1C3 (0.54) AKR1C3AKR1C1SLC18A3GRIN2BRAB9A
SCHEMBL5007409 0.83 AKR1C3 (0.51) AKR1C3AKR1C1LTA4HCYP2D6CYP2C19
SCHEMBL5009507 0.79 AKR1C3 (0.54) AKR1C3AKR1C1SLC18A3GRIN2BRAB9A
SCHEMBL447088 0.77 LTA4H (0.72) SLC18A3GRIN2BLTA4HCYP2D6CYP2C19
SCHEMBL18937694 0.77 ESR2 (0.41) AKR1C3AKR1C1SLC18A3RAB9ANPC1
SCHEMBL7388336 0.77 AKR1C3 (0.74) AKR1C3AKR1C1GRIN2BRAB9ANPC1
SCHEMBL11665023 0.77 AKR1C3 (0.74) AKR1C3AKR1C1GRIN2BRAB9ANPC1
SCHEMBL717453 0.77 AKR1C3 (0.74) AKR1C3AKR1C1GRIN2BRAB9ANPC1
SCHEMBL17124882 0.76 SLC18A3 (0.44) AKR1C3AKR1C1SLC18A3RAB9ANPC1
SCHEMBL664284 0.75 NPC1 (0.79) AKR1C3AKR1C1SLC18A3GRIN2BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 AKR1C3 1826/4885AKR1C1 2592/4885SLC18A3 3846/4885
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 AKR1C3 1826/4885AKR1C1 2592/4885SLC18A3 3846/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 AKR1C3 1826/4885AKR1C1 2592/4885SLC18A3 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.